Use of Second Generation Tyrosine Kinase Inhibitors for Second-Line Treatment of Chronic Myeloid Leukemia After Imatinib Failure

被引：4
|
作者：
Buyukasik, Yahya [1 ]
机构：
[1] Hacettepe Univ, Fac Med, Dept Hematol, TR-06100 Ankara, Turkey
来源：
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI | 2011年 / 21卷 / 02期
关键词：
Chronic myeloid leukemia; Targeted therapy; Imatinib; Dasatinib; Nilotinib; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL MUTATIONS; CHRONIC-PHASE; FOLLOW-UP; CYTOGENETIC RESPONSES; EUROPEAN LEUKEMIANET; SUBOPTIMAL RESPONSE; DASATINIB; RESISTANT; NILOTINIB;
D O I：
10.4999/uhod.11012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Invention of imatinib was a great step for much more successful clinical management of chronic myeloid leukemia (CML). Now, two other tyrosine kinase inhibitors (TKIs) are available both for first-line and later treatments of CML. In Turkey, currently 2nd line TKIs are indicated only for imatinib failure. This review will evaluate indications for changing imatinib with dasatinib or nilotinib, success of the 2nd line agents in the second-line treatment and some important properties of these agents.
引用
收藏
页码：4 / 9
页数：6
相关论文
共 50 条
  • [1] Long-Term Outcomes in the Second-Line Treatment of Chronic Myeloid Leukemia A Review of Tyrosine Kinase Inhibitors
    Jabbour, Elias
    Cortes, Jorge
    Kantarjian, Hagop
    CANCER, 2011, 117 (05) : 897 - 906
  • [2] Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
    Tinsley, Sara M.
    JOURNAL OF CLINICAL NURSING, 2010, 19 (9-10) : 1207 - 1218
  • [3] Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia
    Eghtedar, Alireza
    Kantarjian, Hagop
    Jabbour, Elias
    O'Brien, Susan
    Burton, Elizabeth
    Garcia-Manero, Guillermo
    Verstovsek, Srdan
    Ravandi, Farhad
    Borthakur, Gautam
    Konopleva, Marina
    Quintas-Cardama, Alfonso
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (04) : 477 - 484
  • [4] Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy
    Smith, B. Douglas
    Liu, Jun
    Latremouille-Viau, Dominick
    Guerin, Annie
    Fernandez, Daniel
    Chen, Lei
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (05) : 817 - 827
  • [5] Chronic Myeloid Leukemia and Second-Generation Tyrosine Kinase Inhibitors: When, How, and Which One?
    Jabbour, Elias
    Kantarjian, Hagop
    Cortes, Jorge
    SEMINARS IN HEMATOLOGY, 2010, 47 (04) : 344 - 353
  • [6] Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors
    Garcia-Gutierrez, Valentin
    Hernandez-Boluda, Juan Carlos
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 14
  • [7] Which Second-Line Tyrosine Kinase Inhibitor(s) for Chronic Myeloid Leukemia?
    Schwab, Robert D.
    Luger, Selina M.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (07) : 757 - 769
  • [8] Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
    Breccia, M.
    Alimena, G.
    CURRENT CANCER DRUG TARGETS, 2012, 12 (04) : 391 - 401
  • [9] Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia
    Swords R.
    Alvarado Y.
    Cortes J.
    Giles F.J.
    Current Hematologic Malignancy Reports, 2007, 2 (2) : 83 - 88
  • [10] Recommendations on monitoring and second-line therapy for chronic myeloid leukemia
    Hochhaus, A.
    Overkamp, F.
    Lange, T.
    Mohr, A.
    Ottmann, O.
    Coutre, P.
    Haferlach, T.
    ONKOLOGE, 2010, 16 (07): : 701 - 708
12345